Mesoblast (ASX:MSB) share price tumbles 8% giving back most of yesterday's gains

What's happened to the company's shares?

| More on:
a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price was in reverse today after surging more than 11% on Monday. The allogeneic cellular medicines company announced a trial update to its rexlemestrocel-L drug.

At the closing bell, Mesoblast shares finished the day down 8.68% to $1.735.

Why are Mesoblast shares falling?

Investors appeared to be taking profit off the table, sending the Mesoblast share price lower.

Following yesterday's astronomical gains, trading volumes rocketed to levels not seen since early September.

The company provided results from its phase 3 trial of rexlemestrocel-l in 565 patients suffering from chronic heart failure.

Presented at the American Heart Association (AHA) annual Scientific Sessions, Mesoblast highlighted a key takeaway from the landmark study. This related to the significant relationship between the presence of systemic inflammation and the treatment benefit with rexlemestrocel-L.

In particular, a single dose of rexlemestrocel-L, along with standard of care, reduced the incidence of heart attacks or strokes by 65% across all patients. This figure is compared against standard of care alone.

In addition, the same dosage of rexlemestrocel-L with standard of care diminished the incidence of cardiovascular death, heart attacks, or strokes by 33%.

How does rexlemestrocel-L work?

Rexlemestrocel-L reduces inflammatory cytokine production by immune cells, generating improved local networks of blood vessels within the damaged heart. In turn, this lowers the risk of plaque rupture in major arteries.

Heart failure affects around 6.5 million people in the United States and 26 million people globally, with rates increasing every year. The mortality rate approaches 50% at 5 years as patients progress beyond New York Heart Association (NYHA) class II disease.

Mesoblast share price summary

In the past 12 months, Mesoblast shares have disappointed investor expectations, failing to take off. The company's share price is down by almost 50% since this time last year, and down almost 23% year-to-date.

It's worth noting that Mesoblast shares are a long way off their 52-week high of $5.05.

Based on today's price, Mesoblast presides a market capitalisation of around $1.13 billion, with approximately 648.7 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »